![]() | Alan S CohenBoston University School of Medicine, Boston, Massachusetts, USA | Hepatobiliary Surgery and Liver Transplantation Lahey Clinic, Burlington, MA, 01805, USA | Thorndike ... |
KOL Resume for Alan S Cohen
Year | |
---|---|
2005 | Boston University School of Medicine, Boston, Massachusetts, USA |
2002 | Hepatobiliary Surgery and Liver Transplantation Lahey Clinic, Burlington, MA, 01805, USA |
2000 | Amyloid Program, Boston University School of Medicine, Boston, Massachusetts, 02118 |
1996 | From the Neurological Unit (Drs. Bergethon and Sabin) and the Arthritis Center (Drs. Simms, Cohen, and Skinner), Boston City Hospital, and the Departments of Neurology (Drs. Bergethon and Sabin) and Medicine (Drs. Simms, Cohen, and Skinner), Boston University School of Medicine, Boston, MA; and the Department of Surgery (Dr. Lewis), The New England Deaconess Hospital, Boston, MA. Supported by grants from the National Institutes of Health (AR40414, AR20613, RR533) and the Boston City Hospital Fund for Excellence. Received February 22, 1995. Accepted in final form December 8, 1995. Address correspondence to Dr. P.R. Bergethon, The Neurological Unit, Boston City Hospital, 818 Harrison Avenue, Boston, MA 02118. Department of Medicine, Cukurova University, Adana, Turkey |
1994 | Boston University School of Medicine, Boston, Massachusetts |
1993 | From the Amyloid Treatment and Research Center, Arthritis Center (Berg, Kane, Cohen, Skinner), and the Departments of Biochemistry (Troxler), Otolaryngology (Grillone), and Pathology (Kasznica), Boston University School of Medicine, Boston, Massachusetts. |
1992 | Department of Medicine and Thorndike Memorial Laboratory, Boston City Hospital, Boston, Massachusetts, USA Boston City Hospital, Boston University School of Medicine, Massachusetts. Hospital Clinic, University of Barcelona, Spain |
1991 | Arthritis Center, Department of Medicine, Boston University, 02118, Boston, MA, USA |
1990 | Arthritis Center and Department of Medicine, Boston University School of Medicine, 02118, Boston, MA, USA Department of Biochemistry, Boston University School of Medicine, MA 02118 |
1989 | Department of Medicine, Boston University School of Medicine, Boston, MA, USA Arthritis Center, Boston University School of Medicine, Boston, Massachusetts |
1987 | Boston, Massachusetts, USA |
1986 | Thorndike Memorial Laboratory and Division of Medicine, Boston City Hospital, and the Arthritis Center, Boston University School of Medicine, Boston, Massachusetts Boston University School of Medicine, 02118, Boston, MA, USA Department of Anatomy, McGill University, Montreal, Quebec, Canada H3A 2B2 |
1985 | Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA Department of Medicine and the Thorndike Memorial Laboratory, Boston City Hospital, Arthritis Center, Boston University School of Medicine; the Department of Rheumatology and Immunology, Brigham and Women's Hospital; the Department of Medicine, Harvard Medical School; and the Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts Arthritis Center, Boston University School of Medicine, 71 East Concord Street, Boston, MA 02118 |
1984 | Thorndike Memorial Laboratory, Division of Medicine, and the Mallory Institute of Pathology, Boston City Hospital; Arthritis and Connective Tissue Disease Section, Boston University School of Medicine; and Section of Medical Oncology, Department of Medicine, New England Deaconess Hospital, Harvard Medical School; Boston, Massachusetts, USA From the Cardiology and Arthritis and Connective Tissue Disease Sections, the Thomdike Memorial Laboratory and the Division of Medicine, Boston City Hospital, Boston University School of Medicine, Boston, Massachusetts. Conrad Wesselhoeft Professor of Medicine |
1983 | Conrad Wesselhoeft Professor of Medicine, Boston University School of Medicine |
1982 | The Arthritis and Connective Tissue Disease Section, the Thorndike Memorial Laboratory and Division of Medicine, Boston City Hospital and University Hospital, Boston University School of Medicine , Boston, MA, 02118 Boston City Hospital, Boston |
1981 | From the Department of Medicine, Thorndike Memorial Laboratory, Boston City Hospital, and Boston University School of Medicine, Boston, Massachusetts. Department of Dermatology, University of Uppsala, Uppsala, Sweden Thorndike Memorial Laboratory and Division of Medicine, Boston City Hospital, Boston, MA, USA |
1980 | Thorndike Memorial Laboratory and the Department of Medicine, Boston City Hospital, the Arthritis Center of Boston University School of Medicine, Boston University Medical Center, and Fourth Department of Medicine, University of Helsinki, Helsinki, Finland |
1979 | Boston City Hospital, Thorndike 314, 818 Harrison Avenue, Boston, Massachusetts 02118 |
Alan S Cohen: Influence Statistics
Concept | World rank |
---|---|
amyloidosis injection | #1 |
age factors amyloidosis | #1 |
sensitivity cardiac amyloidosis | #1 |
predilection amyloid | #1 |
biochemical nature disease | #1 |
carpal synovium | #1 |
risk” relatives | #1 |
ambulatory residents patients | #1 |
fine structural analysis | #1 |
medical residents control | #1 |
amyloid ” | #1 |
blood rheumatic | #1 |
amyloidosis pathologic | #1 |
progression neurologic disease | #1 |
of220 10 mmhg | #1 |
new mutation dna | #1 |
antimouse aa | #1 |
peritoneum amyloid | #1 |
clinical evidence suggestive | #1 |
pcomponents plasma protein | #1 |
coding alpha form | #1 |
caused amyloidosis | #1 |
interphalangeal area | #1 |
elevation metastatic | #1 |
myocardial technetium99m | #1 |
detectable aminoterminus | #1 |
new transthyretin mutation | #1 |
aminophylline amyloidosis | #1 |
lysozyme 6th | #1 |
blending ideas | #1 |
characterization p‐component | #1 |
amyloidosis guinea pigs | #1 |
position transthyretin | #1 |
acute suppurative arthritis | #1 |
amyloid electron microscopy | #1 |
component minor constituent | #1 |
increased atrial thickness | #1 |
retention period release | #1 |
inherited type amyloidosis | #1 |
16 synovial membranes | #1 |
basotubules pericellular matrix | #1 |
portuguese texas | #1 |
depressed prealbumin levels | #1 |
blood lymphatic capillaries | #1 |
prognosis amyloid | #1 |
polyneuropathy demonstration | #1 |
german descent fap | #1 |
“continuous endothelium | #1 |
human aef factor | #1 |
ttr gene fap2 | #1 |
Open the FULL List in Excel | |
Prominent publications by Alan S Cohen
The clinical features of elderly‐onset rheumatoid arthritis. A comparison with younger‐onset disease of similar duration
[ PUBLICATION ]
Patients with elderly-onset rheumatoid arthritis (EORA) may represent a clinical subset of individuals who differ prognostically and therapeutically from patients with younger-onset disease (YORA). In order to test this hypothesis, we reviewed the records of 212 patients with rheumatoid arthritis and grouped them according to age at onset above or below 60 years old. Seventy-eight EORA patients and 134 YORA patients with disease duration of less than or equal to 10 years were used for a ...
Known for Onset Rheumatoid | Patients Eora | Disease Duration | Clinical Presentation | Rheumatica Pmr |
Two hundred and seventy-seven patients with a broad spectrum of neoplastic diseases, including 10 classes of solid tumours and three classes of haematologic malignancies, were retrospectively surveyed, and from the same sample of plasma or serum their concentrations of serum amyloid A (SAA), serum amyloid P component (SAP), C-reactive protein (CRP), and carcinoembryonic antigen (CEA) were measured. SAA levels varied from 105 ng/ml to 105,000 ng/ml, and mean SAA levels were higher in ...
Known for Serum Amyloid Saa | Phase Protein | Broad Spectrum | Crp Levels | Limited Disease |
Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
[ PUBLICATION ]
PURPOSE: A clinical trial designed to test whether treatment with melphalan, prednisone, and colchicine (MPC) is superior to colchicine (C) alone was performed in patients with primary amyloidosis (AL), a nonmalignant plasma cell dyscrasia.
PATIENTS AND METHODS: Patients were randomized to MPC or C with stratification according to sex, time from diagnosis to study entry (ie, less than 3 months or 3 to 12 months), and dominant organ system involvement (ie, cardiac, renal, neurologic, or ...
Known for Primary Amyloidosis | Colchicine Patients | Melphalan Prednisone | Survival Treatment | 3 Months |
THE ROLE OF INTERLEUKIN 1 IN ACUTE PHASE SERUM AMYLOID A (SAA) AND SERUM AMYLOID P (SAP) BIOSYNTHESIS*
[ PUBLICATION ]
The acute phase SAA and SAP profiles have been compared for localized and endotoxin induced inflammation in LPS responder and nonresponder strains of mice. The SAP profile can reflect a delay with respect to the start of the increase. Its maximum is on the order of ten times the nonacute phase concentration and elevated concentrations are sustained 24 to 48 hours after SAA concentration is rapidly decreasing to normal. The role of Interleukin 1, known to have an essential role in SAA ...
Known for Serum Amyloid | Acute Phase | Interleukin 1 | Concentration Saa | Purified Mouse |
Localized Amyloidosis of the Head and Neck and Upper Aerodigestive and Lower Respiratory Tracts
[ PUBLICATION ]
Seven cases of localized amyloidosis limited to structures of the head and neck and upper aerodigestive and lower respiratory tracts evaluated and treated at Boston University Hospitals in a recent 7-year period were reviewed. Negative Congo red staining of abdominal adipose aspiration biopsy or rectal biopsy specimens established that the amyloidosis was not systemic. Localized amyloidosis occurred in discrete masses in a variety of sites in the aerodigestive tract including the orbit, ...
Known for Localized Amyloidosis | Upper Aerodigestive | Respiratory Tract | Head Neck | Nasopharyngeal Diseases |
The 1971 preliminary criteria for the classification of systemic lupus erythematosus (SLE) were revised and updated to incorporate new immunologic knowledge and improve disease classification. The 1982 revised criteria include fluorescence antinuclear antibody and antibody to native DNA and Sm antigen. Some criteria involving the same organ systems were aggregated into single criteria. Raynaud's phenomenon and alopecia were not included in the 1982 revised criteria because of low ...
Known for 1982 Revised Criteria | Systemic Lupus | Serologic Tests | Native Dna | Organ Systems |
Different regulatory mechanisms for serum amyloid A and serum amyloid P synthesis by cultured mouse hepatocytes.
[ PUBLICATION ]
Regulation of the in vitro synthesis of the serum amyloid proteins A and P has been studied with hepatocyte cultures from CBA/J and C3H/HeJ mice. Liver cells were isolated by the collagenase perfusion technique and established for 48 h in the presence of fetal calf serum. Viable cells could then be maintained in the absence of serum for at least 72 h and in the presence of serum for up to 2 weeks. Serum amyloid A synthesis differed from serum amyloid P synthesis in three significant ...
Known for Serum Amyloid | Liver Cells | C3h Mice | Inbred Cba | Mouse Hepatocytes |
Total (plethysmography) and capillary (radioisotope disappearance rate) fingertip flows were measured in 24 patients with Raynaud's phenomenon and compared to 10 normal subjects in a warm room and during reflex sympathetic nerve stimulation by body cooling. Arteriovenous shunt flow was estimated by subtraction of capillary from total flow. Patients with Raynaud's phenomenon had a significantly smaller capillary flow in both warm (6.4 vs. 10 ml per 100 g per minute) and cool (4.0 vs. 7.0 ...
Known for Raynauds Phenomenon | Normal Subjects | Patients Raynaud | Blood Flow | Body Cooling |
A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin
[ PUBLICATION ]
Amyloid fibrils were isolated from amyloid-laden tissue obtained from a chronic hemodialysis patient with carpal tunnel syndrome. After solubilization in guanidine HCl, a significant amount of the protein was located in a homogeneous low molecular weight fraction. The protein was found to be identical to beta 2-microglobulin, with regard to its molecular weight of 11,000, amino acid composition and 16 amino-terminal amino acids: ...
Known for Chronic Hemodialysis | New Form | Amyloid Protein | Molecular Weight | Beta 2microglobulin |
Severe intrahepatic cholestasis in primary amyloidosis A report of four cases and a review of the literature
[ PUBLICATION ]
Liver involvement occurs frequently in patients with systemic amyloidosis, but jaundice is rare. The clinical and histopathologic features are described in four of 78 patients (5.3 per cent) with primary amyloidosis in whom severe intrahepatic cholestasis developed. The data on an additional eight patients recorded in the literature were reviewed. Criteria for inclusion were a tissue diagnosis of amyloidosis, a serum bilirubin level greater than 5 mg/100 ml, histopathologic evidence for ...
Known for Intrahepatic Cholestasis | Primary Amyloidosis | 12 Patients | Bile Ducts | Liver Involvement |
Key People For Serum Amyloid
Alan S Cohen:Expert Impact
Concepts for whichAlan S Cohenhas direct influence:Serum amyloid, Amyloid fibrils, Localized amyloidosis, Amyloid fibril, Amyloid deposits, Rheumatoid arthritis, Amyloid protein, Synovial fluid.
Alan S Cohen:KOL impact
Concepts related to the work of other authors for whichfor which Alan S Cohen has influence:Systemic lupus erythematosus, Sle patients, Lupus nephritis, Rheumatoid arthritis, Amyloid fibrils, Autoimmune diseases, Antiphospholipid syndrome.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |